Wednesday, June 21, 2017 10:54:17 AM
Guru Score: 40%
PRICE/SALES RATIO: [FAIL]
The prospective company should have a low Price/Sales ratio. However, NAK's P/S is not available which means an opinion cannot be rendered at the present time on this variable. This is the most important variable according to this methodology, and therefore the remainder of the analysis will be provided for informational purposes.
TOTAL DEBT/EQUITY RATIO: [PASS]
Less debt equals less risk according to this methodology. NAK's Debt/Equity of 0.00% is exceptional, thus passing the test.
PRICE/RESEARCH RATIO: [PASS]
This methodology considers companies in the Technology and Medical sectors to be attractive if they have low Price/Research ratios. NAK is neither a Technology nor Medical company. Therefore the Price/Research ratio is not available and, hence, not much emphasis should be placed on this particular variable.
PRELIMINARY GRADE: No Interest in NAK At this Point
Is NAK a "Super Stock"? NO
LONG-TERM EPS GROWTH RATE: [FAIL]
This methodology looks for companies that have an inflation adjusted EPS growth rate greater than 15%. NAK's inflation adjusted EPS growth rate is not available. Hence, this methodology cannot analyze this criterion at the present time.
FREE CASH PER SHARE: [FAIL]
This methodology looks for companies that have a positive free cash per share. Companies should have enough free cash available to sustain three years of losses. This is based on the premise that companies without cash will soon be out of business. NAK's free cash per share of -0.07 fails this criterion.
THREE YEAR AVERAGE NET PROFIT MARGIN: [FAIL]
This methodology looks for companies that have an average net profit margin of 5% or greater over a three year period. NAK's three year net profit margin, which averages 0.00%, does not pass this criterion.
Everything I say,is only my opinion. DO not rely on anything I post,as buy or sell advice. DO your own homework.
Recent NAK News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:26:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 11:46:24 AM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 12/29/2023 08:52:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/15/2023 03:49:59 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/15/2023 10:05:59 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/05/2023 10:01:05 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM